Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.37 |
| ▸ | CTSS | P25774 | 7/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4955709 | 0.90 | CTSK (0.34) | CTSKCTSSITGB3ITGA2BCTSL | |
| SCHEMBL299855 | 0.84 | ITGB3 (0.43) | CTSKCTSSITGB3ITGA2BHDAC4 | |
| SCHEMBL27589805 | 0.80 | ANPEP (0.35) | — | |
| SCHEMBL1733549 | 0.79 | KMT2A (0.39) | CTSKCTSSTSHR | |
| SCHEMBL4730477 | 0.75 | ITGB3 (0.48) | CTSKCTSSITGB3ITGA2BHDAC4 | |
| SCHEMBL2769978 | 0.74 | FOLH1 (0.56) | CTSKCTSS | |
| SCHEMBL1318658 | 0.74 | FOLH1 (0.56) | CTSKCTSS | |
| SCHEMBL1324835 | 0.74 | FOLH1 (0.56) | CTSKCTSS | |
| SCHEMBL6168892 | 0.73 | AAK1 (0.39) | CTSKCTSSCTSLHDAC4HDAC1 | |
| SCHEMBL14125028 | 0.72 | CTSK (0.48) | CTSKCTSSCTSLCTSBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368576-B2 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | PROBIODRUG AG (DE) | 2008-05-06 | — | — | US | disclosed |
| US-7368421-B2 | Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis | PROBIODRUG AG (DE) | 2008-05-06 | — | — | US | disclosed |
| US-7335645-B2 | Effectors of dipeptidyl peptidase IV for topical use | PROBIODRUG AG (DE) | 2008-02-26 | — | — | US | disclosed |
| US-20070207946-A1 | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels | POSPISILIK ANDREW J | 2007-09-06 | — | — | US | disclosed |
| EP-1792910-A2 | Effectors of dipeptidyl peptidase IV for topical use | Probiodrug AG (DE) | 2007-06-06 | — | — | EP | disclosed |
| EP-1206485-B1 | NEW EFFECTORS OF DIPEPTIDYL PEPTIDASE IV FOR TOPICAL USE | PROBIODRUG AG (DE) | 2007-03-21 | — | — | EP | disclosed |
| US-20060293248-A1 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | PROBIODRUG AG | 2006-12-28 | — | — | US | disclosed |
| US-7109347-B2 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | PROBIODRUG AG (DE) | 2006-09-19 | — | — | US | disclosed |
| US-6949515-B2 | Effectors of dipeptidyl peptidase IV for topical use | PROBIODRUG AG (DE) | 2005-09-27 | — | — | US | disclosed |
| US-20050209159-A1 | Effectors of dipeptidyl peptidase IV for topical use | PROBIODRUG AG (DE) | 2005-09-22 | — | — | US | disclosed |
| EP-1399470-A2 | DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES AS ANTI-CANCER AGENTS | Probiodrug AG (DE) | 2004-03-24 | — | — | EP | disclosed |
| US-20030176357-A1 | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels | PROSIDION LIMITED (GB) | 2003-09-18 | — | — | US | disclosed |
| US-20030130199-A1 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | PROBIODRUG (DE) | 2003-07-10 | — | — | US | disclosed |
| US-20030119750-A1 | Use of dipeptidyl peptidase IV inhibitors | PROBIODRUG (DE) | 2003-06-26 | — | — | US | disclosed |
| US-20030092630-A2 | Amino acid side chain-modified substrates of the enzyme; obtaining locally limited inhibition; treating inflammation, psoriasis, periodontitis, allergies, arthritis, tumors or autoimmune diseases | PROBIODRUG AG (DE) | 2003-05-15 | — | — | US | disclosed |
| WO-2003015775-A1 | NEW DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES FOR LOWERING BLOOD PRESSURE LEVELS | PROBIODRUG AG (DE) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003002595-A2 | DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES AS ANTI-CANCER AGENTS | PROBIODRUG AG (DE) | 2003-01-09 | — | — | WO | disclosed |
| US-20020165164-A1 | New effectors of dipeptidyl peptidase IV for topical use | DEMUTH HANS-ULRICH (DE) | 2002-11-07 | — | — | US | disclosed |
| EP-1206485-A2 | NEW EFFECTORS OF DIPEPTIDYL PEPTIDASE IV FOR TOPICAL USE | Probiodrug AG (DE) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001014318-A2 | NEW EFFECTORS OF DIPEPTIDYL PEPTIDASE IV FOR TOPICAL USE | PROBIODRUG AG (DE) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092630-A2 | Amino acid side chain-modified substrates of the enzyme; obtaining locally limited inhibition; treating inflammation, psoriasis, periodontitis, allergies, arthritis, tumors or autoimmune diseases | DNPEP, PREP, ENPEP | CTSK 633/4885CTSS 443/4885ITGB3 1963/4885 |
| US-20060293248-A1 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | DPP4, DPP3, DNPEP | CTSK 952/4885CTSS 560/4885ITGB3 1066/4885 |
| US-20020165164-A1 | New effectors of dipeptidyl peptidase IV for topical use | DNPEP, PREP, DPP4 | CTSK 741/4885CTSS 773/4885ITGB3 1407/4885 |
| US-20030130199-A1 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | DPP4, DPP3, DNPEP | CTSK 952/4885CTSS 560/4885ITGB3 1066/4885 |
| US-20030119750-A1 | Use of dipeptidyl peptidase IV inhibitors | DPP4, DPP3, DPP7 | CTSK 1467/4885CTSS 833/4885ITGB3 4186/4885 |
| US-20050209159-A1 | Effectors of dipeptidyl peptidase IV for topical use | DNPEP, PREP, DPP4 | CTSK 673/4885CTSS 757/4885ITGB3 1249/4885 |
| US-20070207946-A1 | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels | DPP4, DPP3, DPP9 | CTSK 436/4885CTSS 608/4885ITGB3 3140/4885 |
| US-20030176357-A1 | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels | DPP4, DPP3, DPP9 | CTSK 436/4885CTSS 608/4885ITGB3 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.